GRObio, a spinout from the George Church Lab at Harvard University, has encountered significant hurdles lately. Founded in 2016, GRObio focuses on developing therapeutic proteins built on nonstandard amino acids (NSAAs). Despite its pioneering approach, the company is undergoing a period of
Immunovant, a biotechnology company known for its innovative treatments for autoimmune diseases, has recently announced a significant shift in its development strategy. Despite late-stage successes with its experimental drug batoclimab, the company has decided to momentarily hold back on seeking
Ivan Kairatov is a Biopharma expert with deep knowledge of tech and innovation in the industry and experience in research and development. Today, we are discussing Med-Life Discoveries (MLD), their mission, and the promising results of their Phase I study on PPI-1011, a synthetic plasmalogen
Bioprinting has emerged as a revolutionary bioengineering technique that utilizes the principles of 3D printing to create tissue-like structures embedded with living cells. Since its inception in 1988, this technology has experienced tremendous growth, advancing from its original concept to today’s
In a surprising move, Sutro Biopharma has decided to undertake a sweeping restructuring plan with the primary goal of conserving capital, leading to a nearly 50% reduction in its workforce, the ousting of CEO Bill Newell, the discontinuation of its lead drug candidate luveltamab tazevibulin
The ongoing opioid crisis has affected countless lives, leaving individuals and families grappling with addiction and its devastating consequences. Amid this turmoil, researchers funded by the National Institutes of Health (NIH) have been diligently working on a novel solution that could change the
